Navigation Links
Regular exercise reduces risk of blood clots
Date:11/20/2007

Leiden, The Netherlands November 20, 2007 According to a new study published in Journal of Thrombosis and Haemostasis, regular participation in sports reduces the risk of developing blood clots by 39 percent in women and 22 percent in men.

Researchers from Leiden University Medical Center in the Netherlands evaluated 7,860 people aged 18-70. Patients who had suffered their first blood clot in a leg vein or lung artery were compared with control subjects who had never experienced blood clots. 31 percent of the patients and 40 percent of the control group participated in sports on a regular basis.

Overall figures for both sexes showed that participating in sports at least once per week, regardless of the type of sport or its intensity, reduced the risk of developing a blood clot in a lung artery by 46 percent and a blood clot in a leg vein by 24 percent.

Women were shown to be even more likely to reap the benefits of regular sporting activities than men, says F.R. Rosendaal, co-author of the study. When we excluded women who were pregnant or receiving oral contraceptive or hormone replacement therapy all possible causes of blood clots the risk for women was reduced by 55 percent.

The authors note that, while strenuous activity is known to increase the risk of blood clot development in the elderly, regular exercise is also shown to greatly benefit the heart, and that the net effect of elderly sports participation may be positive.

The findings also show that people who did not participate in sports were more than four-times as likely to develop a blood clot if they were obese (with a body mass index of 30 or greater) than lean (with a body mass index of less than 25).

When we looked at the results, we found that, overall, the mere fact that people took part in a sporting activity at least once a week was enough to lower their risk of blood clots, say the authors.


'/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
Source:Eurekalert

Page: 1

Related medicine news :

1. Landauer, Inc. Declares Regular Cash Dividend
2. Drug, Pacemaker Fight Irregular Heartbeat
3. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
4. Personal chaos in HIV patients lives may be a barrier to regular medical care, UCLA Study Shows
5. Regular Eye Screens Spot Diabetic Vision Trouble
6. Colgate Declares Regular Quarterly Dividends
7. Robbins & Myers Announces Regular Quarterly Cash Dividend
8. Regular Exercise Helps Fight Heart Failure
9. Exercise and yoga improves quality of life in women with early-stage breast cancer
10. Studies Prove Exercise Can Heal the Body Mind and Soul
11. 1 in 3 Varsity Athletes Has Exercise-Induced Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Skincare Industry Newcomer Shines 51058 1Skincare Industry Newcomer Shines 51058 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 1For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 3Allied World Schedules Second Quarter 2009 Earnings Announcement and Conference Call 51052 1